Journal of Clinical Investigation · 2017 · 108 citations · 19 references
MedicineImmunologyOncologyCancer ImmunologyTumor ImmunologyTumor MicroenvironmentCancer ImmunotherapyChemokine SignalingImmune Cell InfiltrationKidney CancerRenal Cell CarcinomaTumor Immune MicroenvironmentAntitumor Cytokine ResponsesCd4 Positive T CellsCd4+ Tumor-infiltrating LymphocytesChemokine Receptor AntagonismChemokine Receptor Cxcr4 AntagonismChemokines In Tumor MicroenvironmentTh1 Th2 BalanceTumor Microenvironment Effects
Elevated expression of the chemokine receptor CCR4 in tumors is associated with poor prognosis in several cancers. Here, we have determined that CCR4 was highly expressed in human renal cell carcinoma (RCC) biopsies and observed abnormal levels of CCR4 ligands in RCC patient plasma. An antagonistic anti-CCR4 antibody had antitumor activity in the RENCA mouse model of RCC. CCR4 inhibition did not reduce the proportion of infiltrating leukocytes in the tumor microenvironment but altered the phenotype of myeloid cells, increased NK cell and Th1 cytokine levels, and reduced immature myeloid cell infiltrate and blood chemokine levels. In spite of prominent changes in the myeloid compartment, the anti-CCR4 antibody did not affect RENCA tumors in T cell-deficient mice, and treatment with an anti-class II MHC antibody abrogated its antitumor activity. We concluded that the effects of the anti-CCR4 antibody required the adaptive immune system and CD4+ T cells. Moreover, CCL17-induced IFN-γ production was reduced when Th1-polarized normal CD4+ T cells were exposed to the CCR4 ligand, evidencing the involvement of CCR4 in Th1/Th2 regulation. The anti-CCR4 antibody, alone or in combination with other immune modulators, is a potential treatment approach to human solid cancers with high levels of CCR4-expressing tumor-infiltrating leukocytes and abnormal plasma CCR4 ligand levels.
19
CSF-1R inhibition alters macrophage polarization and blocks glioma progression
Stephanie M. Pyonteck, Leila Akkari, Alberto J. Schuhmacher et al. · Nature Medicine · 2013 · 2.5K citations · Full text
Raffaella Bonecchi, Paola Panina‐Bordignon, Daniele D’Ambrosio et al. · The Journal of Experimental Medicine · 1998 · 2K citations · Full text
Michael Gobert, Isabelle Treilleux, Nathalie Bendriss‐Vermare et al. · Cancer Research · 2009 · 744 citations
Life Sciences, Immunology, Oncology +17
Morio Nagira, Shin Takagi, Mayumi Kakizaki et al. · International Immunology · 1999 · 719 citations · Full text